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The effect of cyclosporin A on the hepatic energy 
status and intracellular pH of the liver and its response 
to a fructose challenge has been investigated using 
in vivo phosphorus-31 nuclear magnetic resonance 
spectroscopy in dogs. Three experimental groups 
were studied: (a) control dogs (n = 5), (b) dogs 4 days 
after the creation of an end-to-side portacaval shunt 
(n = 5), and (c) dogs 4 days after portacaval shunt and 
continuous infusion of cyclosporin A (4 mg/kg/day) by 
way of the left portal vein (portacaval shunt plus 
cyclosporin A, n = 5). The phosphorus-31 nuclear 
magnetic resonance spectra were obtained at 81 MHz 
using a Bruker BIOSPEC II 4.7-tesla nuclear mag-
netic resonance system equipped with a 40-cm hori-
zontal bore superconducting solenoid. The phospho-
monoesters (p < 0.01), inorganic phosphate and ATP 
levels (p < 0.05) were decreased significantly in por-
tacaval shunt-treated and in portacaval shunt-plus-
cyclosporin A-treated dogs compared with unshunted 
control dogs. Mter a fructose challenge (750 mg/kg 
body wt, intravenously), fructose-I-phosphate metab-
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olism was reduced in portacaval shunt-treated dogs 
compared with either the normal or portacaval shunt-
plus-cyclosporin A-treated dogs (p < 0.05). Both por-
tacaval shunt- and portacaval shunt-plus-cyclosporin 
A-treated dogs demonstrated a reduced decline in ATP 
levels after fructose infusion when compared with the 
controls (p < 0.05). Immediately after the fructose 
challenge, the intracellular pH decreased from 
7.30 ± 0.03 to 7.00 ± 0.05 in all animals (p < 0.01) and 
then gradually returned to normal over 60 min. These 
data, obtained in vivo using phosphorus-31 nuclear 
magnetic resonance spectroscopy of the liver after a 
portacaval shunt, suggest that: (a) the energy status of 
the liver is reduced in dogs with a portacaval shunt 
compared with that of normal controls and (b) cyclo-
sporin A treatment ameliorates the reduction in he-
patic metabolism normally observed after a fructose 
challenge to the liver with a portacaval shunt. (HEPA-
TOLOGY 1991;13:780-785.) 
The intrinsic hepatotoxicity of cyclosporin A (CsA) is 
well documented in the literature (1-10). Clinically, it 
can be manifested either as an increase in one or more 
liver injury parameters or as a cholestatic syndrome. 
Hepatic regeneration may be crucial during and imme-
diately after transplantation, when the liver recovers 
from the injury experienced during the period of 
ischemic cold preservation and reperfusion. The acute 
effects of CsA on liver regeneration have been investi-
gated recently by several different groups (11-16). These 
studies have shown that CsA may actually enhance the 
hepatocyte's regenerative response after partial hepa-
tectomy. 
In this study, the dog with portacaval shunt (PCS) 
(Eck's fistula) was used. PCS usually is associated with 
hepatic atrophy and low-grade hepatocyte hyperplasia 
(16-21). We have previously shown in this model that 
CsA prevents the atrophy and augments the hyperplasia 
(21). In this report, the effect of CsA treatment on the 
metabolic events caused by PCS is examined in vivo 
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using phosphorus-31 nuclear magnetic resonance 
(SlP-NMR) spectroscopy. Various in vivo studies using 
31 P-NMR spectroscopy (22-24) have reported on the 
intracellular pH (pH), the hepatic content of ATP, sugar 
phosphates and inorganic phosphate (Pi) under basal 
conditions and after a physiological challenge with 
fructose. The only other NMR study relevant to hepatic 
regeneration or hepatocyte growth control was per-
formed in vitro and used perchloric-acid extracts of 
tissue samples to calculate phosphate metabolites (25). 
MATERIALS AND METHODS 
Experimental Design. Fifteen female purebred Beagle dogs 
weighing between 8.5 kg and 15 kg were studied after care and 
conditioning at the University of Pittsburgh Animal Research 
Facility. Three groups of animals were studied: (a) normal dogs 
(control, n = 5); (b) animals subjected to PCS (n = 5); and (c) 
animals subjected to PCS and treated with a continuous 
infusion of CsA (4 mg/kglday) into the left lobes of the liver 
through the left portal vein that had been cannulated at the 
time of the PCS procedure (PCS + CsA, n = 5). The basic 
design of the experiment using other test substances has been 
described previously (19, 20). Four days after the procedure 
and after general anesthesia induced with 20 mg/kg sodium 
pentobarbitone intravenously and ventilation with 2% 
halothane in 50% O2/50% N20, femoral arterial and venous 
catheters were inserted for blood sampling. The proximal 
airway pressure, arterial pressure and blood gases were 
monitored continuously during the experiments using a Gould 
RS3600 recorder and a Radiometer ABL2 instrument (Radi-
ometer America, Westlake, OH), respectively. Body temper-
ature was maintained at 37° C with a heated water pad. 
Laparotomy was performed, and a surface coil was placed over 
the liver for NMR measurements. The left and right hepatic 
lobes were studied separately. 
NMR Measurements. 31P_NMR spectra were acquired on a 
Bruker BIOSPEC II 4.7-tesla NMR system equipped with a 
40-cm horizontal bore superconducting solenoid. A 3.5-cm 
surface coil tuned to the resonance frequency of 3lp nucleus 
(81 MHz at 4.7-tesla) was used both for 31P_NMR spectroscopy 
and for shimming on the water signal. The typical line width 
of the water resonance was 100 Hz. Generally, 3IP_NMR 
spectra were acquired in 4-min blocks of64 transients with an 
approximate 3-sec pulse delay (respiratory cycle) and 90 degree 
pulses. Gating was accomplished with a gating device that was 
armed by the respirator and triggered before each respiratory 
cycle. A 5-mm spherical bulb containing a 0.15 mol/L solution 
of methylenediphosphonic acid (MDP A) (23 ppm downfield 
from phosphocreatine lPCr] at 37° C) in D20 at pH 9 was 
placed in the center of the surface coil to serve as chemical shift 
and signal strength references for pHi and relative concen-
tration measurements. 
A calibration curve for the determination of pH from the 'H P 
chemical shifts of Pi and fructose-I-phosphate (F-I-P) was 
obtained as follows. Liver specimens (4 gm wet wt) obtained 
from a normal dog were homogenized and diluted 1: 4 (wt/vol) 
in physiological saline. The homogenate was centrifuged 
(2,500 rpm) at 4° C for 15 min, and the supernatant (12 mIl was 
transferred to a 30-mm NMR sample tube. A spherical glass 
bulb containing MDPA (0.15 mol/L in D2 0, pH 9.0) was 
centered in the sample as an external standard. Mter the 
addition of 10 mmollL F-1-P (Sigma Chemical Co., St. Louis, 
MO) and 10 mmol/L PCr (Sigma), atitration curve (from pH 
4.24 to pH 9.45) was generated at 37° C. For each pH studied, 
the solution was positioned in the magnet, and 10-min 
acquisitions were accumulated using a 3.5-cm diameter so-
lenoid coil, 90-degree pulses and a 5-sec interpulse delay. The 
3lp chemical shifts of Pi and F-1-P in the 31P __ NMR spectra 
were referenced to the internal signal ofPCr. Titration curves 
were obtained by plotting the 3lp chemical shifts of Pi and 
F -1-P as a function of pH. A least-squares fit was performed to 
establish the titration parameters for each curve. The pH i was 
determined using the following equations (26): 
pHi = pKpi + log ([O"Pi - 3.34]/[5.81 - O"Pi]) 
for Pi, and 
pHi = pKF.1.P + log (O"F.l.P - 3.68)/(7.48 - O"F.l.P) 
for F-1-P, wherepKpi andpKF . I.p are 6.76 and 6.03 and<Tpi and 
<TF . I.P are the observed values of the chemical shift in ppm of 
Pi and F-1-P, respectively, error ± 0.03 pH unit. 
The content of phosphate metabolites (ATP, F-1-P, and Pi) 
in the liver was calculated by cutting out the corresponding 
peaks in the 3IP_NMR spectra from the recording paper, 
weighing each peak and normalizing the data obtained using 
the MDPA peak area as a reference. This agreed satisfactorily 
with computer integration after baseline correction. Mter an 
injection of fructose (750 mg/kg body wt in 30% saline 
administered intravenously over 2 min), hepatic metabolism 
was monitored sequentially with a time resolution of 4 min. 
Statistical Analysis. The statistical analysis of the experi-
mental data for intergroup variations was performed using a 
one-way ANOVA combined with the Fisher test. Student's t 
test for paired data was used to compare the change in 
parameters after fructose within each group. A p value < 0.05 
was considered significant. All results are expressed as mean 
value ± S.E.M. 
RESULTS 
Three typical 81-MHz 31P_NMR spectra obtained 
in vivo from normal control, PCS-treated and PCS-plus-
CsA-treated dogs are shown in Figure 1. The phos-
phomonoester (PM) peak (peak 2) represents the sum of 
signals from various sugar phosphates, glycolytic inter-
mediates and AMP. The chemical shift of the Pi peak 
(peak 3) relative to the external standard (peak 1) 
permitted us to determine the pHi of the liver. This value 
was 7.30 ± 0.05 for all three groups of animals studied. 
The phosphodiester (PD) resonance (peak 4) is the sum 
of glycero-3-phosphocholine, glycerol phosphoeth-
anolamine and other related compounds. The ),-ATP-
phosphate and ~-Aam-phosphate resonances (peak 5) 
occur at about - 2.4 ppm upfield from PCr; the 
a-phosphates of both ATP and ADP (peak 6) occur at 
-7.5 ppm upfield from PCr, and the ~-Aqm resonance 
(peak 7) has a single peak at - 16 ppm upfield from PCr. 
Because the right and left hepatic lobes yielded identical 
31P_NMR spectra, only the left lobes were studied after 
the first two experiments. 
The relative concentrations of the various phosphate 
metabolites in the liver as determined by 31P_NMR 
spectroscopy in vivo are shown for the three groups of 
animals studied in Figure 2. The PM (p < 0.01), Pi 
(p < 0.05) and ATP (p < 0.05) decreased in the presence 
of PCS-treated and in the PCS-plus-CsA-treated dogs 
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FIG. 1. In vivo 31P-NMR spectra of dog liver in normal dog liver 
(control) 4 days after PCS and 4 days after PCS plus continuous 
infusion of CsA in the left portal vein branch (PCS + CsA). Peak 
assignments: (1) MDPA; (2) PM; (3) Pi; (4) PD; (5) 'Y-ATP plus [3-ADP; 
(6) a-ATP plus a-ADP; and (7) [3-ATP. These spectra consisting of 64 
acquisitions were accumulated in 4 min with a -3 sec pulse delay 
(respiratory cycle) and 90-degree pulse. MDPA was used as the 
external reference standard for chemical shift and for intergroup and 
intragroup relative concentration measurements. 
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FIG. 2. Relative phosphate metabolite concentrations in dog liver. 
The relative concentrations of phosphate metabolites in the liver were 
measured by dividing the integrated area under each peak by the 
MDPA area used as an external reference in each experiment. The 
n value for each group was 5. The values of the columns marked with 
asterisks are significantly different from the values of the other 
columns (*p < 0.05, **p < 0.01). 
with respect to the control. The (Pi/ATP) ratio that 
correlates inversely with the energy state of the liver did 
not significantly change in the three groups of dogs 
studied (Fig. 2). 
After the administration of a fructose challenge (Fig. 
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FIG. 3. Effect of a fructose challenge on the in vivo 31P_NMR 
spectrum of normal dog liver. Spectra obtained before fructose (a) and 
8 min after fructose administration (b) administered at a dose of 750 
mg/kg body wt intravenously as a bolus. The difference spectrum is 
labeled (b-aJ. 
3), major changes were observed in the 31P_NMR spectra 
of all three groups. An increase in the sugar phosphates, 
caused by the accumulation of F -1-P, and a reduction in 
the Pi and ATP content of the liver was evident 
immediately. 
The time course of the F -1-P peak for the three groups 
of animals is shown in Figure 4. In the control dogs, the 
F-1-P resonance appeared within the first 4 min after 
the fructose infusion and reached a maximum value in 
the second 4 min. It then decreased rapidly as a result of 
the metabolism of the fructose load. This process was 
complete within 20 min, and the sugar phosphates 
region in the 31P_NMR spectrum returned to pre-
fructose levels. In PCS-treated dogs, the metabolism of 
F -1-P was greatly reduced, as shown by a larger increase 
and a slower decline of the F -1-P resonance in the sugar 
phosphate region (p < 0.05). In contrast, the metab-
olism of the fructose load by the PCS-plus-CsA-treated 
dogs was normal and equivalent to control. 
The ATP level (Fig. 5) decreased significantly 
(p < 0.01) to about 50% of the initial value 8 min after 
the fructose challenge. It began to recover at 12 min and 
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FIG. 4. F-1-P levels in dog liver after a fructose challenge. The time 
course ofF-loP levels in dog liver in the three groups of dogs (control, 
n = 5; PCS, n = 5; PCS + CsA, n = 5) after a fructose load (750 
mg/kg body wt administered intravenously as a 30% solution in saline, 
over 2 min, beginning at 0 time). Values are shown as relative changes 
from basal value at 0 time for the PM area relative to the MDPA area, 
mean ± S.E.M. The asterisk denotes p < 0.05. 
reached a level of about 65% of the prefructose value at 
40 min. The recovery of the hepatic ATP content was 
never complete even 2 hr after the fructose challenge, 
when 
the level is approximately 90% ofthe basal value (results 
not shown). The hepatic ATP level decreased less rapidly 
and to a smaller extent in the PCS-treated and PCS-
plus-CsA-treated dogs (p < 0.05) after the fructose 
challenge. However, the subsequent recovery in ATP 
content paralleled that noted in the controls. The 
difference between shunted and control dogs was sta-
tistically significant (p < 0.05) (Fig. 5). 
The Pi changes noted after fructose are shown in 
Table 1. The Pi was depressed early after the fructose 
challenge (p < 0.01) and returned toward normal values 
as the F-I-P peak disappeared. No statistically sig-
nificant differences among groups were observed. 
After the fructose challenge, the pHi fell from a value 
of approximately 7.3 to 7.0 (p < 0.01) in all three animal 
groups within 12 min and returned to a value close to 
baseline values thereafter (results not shown), con-
firming the findings of an earlier study performed in rat 
liver (28). Forty minutes after the fructose challenge, 
the pHi of the PCS-plus-CsA-treated dogs was not 
significantly different from that noted before the chal-
lenge. In contrast, the pHi of control and PCS-treated 
dogs was still reduced (p < 0.01 and p < 0.05, respec-
tively). 
DISCUSSION 
The advantages of using 31P_NMR spectroscopy to 
study liver metabolism and function have been reviewed 
recently (23). In vivo 31P_NMR spectroscopy allows a 
nondestructive monitoring of tissue pH and a study of 
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FIG. 5. ATP levels after a fructose challenge. The time course of 
intrahepatic ATP levels in three groups of dogs (control, n = 5; PCS, 
n = 5; PCS + CsA, n = 5) after a fructose load (750 mg/kg body wt 
administered intravenously as a 30% solution in saline, over 2 min, 
beginning at 0 time). Values are relative changes from the basal value 
at 0 time for the I3·ATP area relative to the MDPA area, 
mean ± S.E.M. The asterisk (*) denotes p < 0.05. 
the levels of hepatic phosphorus-containing compounds 
associated with energy metabolism (23,24,27). In this 
study, this method was used to investigate the conse-
quences of PCS and PCS in conjunction with cyclo-
sporine treatment on hepatic function and basal energy 
status. The response of the liver to a fructose challenge 
was monitored by examining the changes in ATP, Pi, and 
F-I-P levels within the liver as a function of time (28). 
The dog with a portacaval shunt was chosen as a 
well-established model for studying hepatic atrophy and 
contemporaneous hyperplasia (17-20). The typical 
injury pattern after PCS consists of a severe reduction in 
hepatocyte cell size (atrophy) plus organelle disruption 
and a moderate but persistent stimulation of cell 
renewal (hyperplasia). Insulin and cytosolic extract of 
the regenerating liver are able to restore the hepatocyte 
to normal size and to further stimulate hyperplasia (19, 
20). A disadvantage of earlier studies was that the 
animals had to be killed, and in vitro assays of the 
metabolites of interest could be obtained only at selected 
times. 
Interestingly, despite its recognized potential for 
intrinsic hepatotoxicity (1-10), CsA has been shown to 
have "hepatotrophic" effects after partial hepatectomy 
(11-16) oraPCS (21). Furthermore, CsAdoes not appear 
to either prevent or limit the hepatic regenerative 
response observed when a small-for-size liver is trans-
planted into a larger recipient (29) or when a 
reduced-size liver is used in pediatric recipients (30). 
This study provides new data obtained by in vivo 
examination of the energy status and the metabolic 
responsiveness of the liver in an experimental situation 
that could have clinical relevance. The decline in the 
hepatic-phosphate metabolites observed after partial 
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TABLE 1. Changes observed in hepatic Pi after 
a fructose challenge 
Time Control PCS PCS + CsA 
(min) (n = 5) (n = 5) (n = 5) 
0 100 100 100 
4 75.8 ± 10.2 78.6 ± 8.4 86.2 ± 3.9a 
8 58.2 ± 5.7b 57.8 ± 2.7b 64.4 ± 6.0b 
12 63.8 ± 4.6b 62.8 ± 3.3b 73.4 ± 8.1a 
16 89.0 ± 3.7a 74.2 ± 4.9b 89.8 ± 8.2 
20 109.0 ± 5.0 92.0 ± 7.4 10l.2 ± 9.9 
24 113.0 ± 8.3 105.4 ± 9.5 110.6 ± 8.2 
28 116.8 ± 6.6 112.0 ± 8.8 116.8 ± 8.6 
32 109.2 ± 9.7 116.4 ± 11.3 12l.4 ± 7.3a 
36 106.4 ± 10.4 118.2 ± 12.0 12l.8 ± 8.0 
40 105.0 ± 8.9 113.6 ± 10.6 117.4 ± 8.8 
The time course of hepatic Pi changes in three groups of dogs 
(control, PCS and PCS + CsA) after a fructose load (750 mg/kg body 
wt administered intravenously as a 30% solution in saline, more than 
2 min, beginning at 0 time). Values are mean ± S.E.M. Changes 
observed over time were analyzed statistically with Student's t test for 
paired data (a p < 0.05, bp < 0.01, vs. 0 time) and among groups by 
one-way ANOVA test and the Fisher test. 
hepatectomy by in vitro studies (25) has been confirmed 
in the PCS model and in vivo. The effect of portal CsA 
infusion on these parameters was also determined. 
U sing a fructose challenge as a test of metabolic 
responsiveness, the clearance of F-1-P in PCS dogs 
treated with CsA was found to be similar to that 
observed in the control and occurred considerably more 
rapidly than that observed in PCS dogs not receiving 
CsA treatment. 
An apparent discrepancy arises when one considers 
the total balance of phosphates in the data. After 
fructose infusion, negative changes in ATP and Pi and 
positive changes in F-1-P did not seem to add up to 
zero in all single time points. In particular, when phos-
phorylation occurred (0 to 12 min after fructose), more 
phosphate is seen by 31P-NMR spectra in the PM region 
of the PCS-treated animals. In the same time period, the 
concomitant drop of ATP is larger only in the control 
~oupI and the decrease in Pi is not significantly 
dIfferent among the three groups. One possible expla-
nation could lie in the slightly greater decrease in Pi in 
the PCS-treated dogs at most time points. Another 
possibility is that the low signal/noise ratio of the in vivo 
experiments and the proximity of the PM and Pi peaks 
in the 31P_NMR spectra limit an accurate measurement 
of relative changes in the two areas. Finally, the rapid 
changes in Pi could be underestimated in the 4-min time 
frame of our study. Under the present 31P_NMR protocol 
(3-sec repetition), the phosphate resonances are not 
likely to be significantly saturated (31), allowing us to 
relatively quantify the changes of the various phosphate 
metabolite concentration over time. These findings 
suggest that CsA preserves the capacity of the liver to 
metabolize a fructose load after a PCS treatment. This 
may reflect the fact that intracellular levels of the Pi that 
inhibits AMP degradation (32) are better preserved. 
Also, it is interesting that the changes for pH. noted in 
this study are consistent with data obtained ~sing the 
perfused rat liver (28), suggesting that the fall in pH. 
after fructose is caused mainly by production of hy~ 
drogen ions accompanying the formation of lactate from 
fructose. 
How these biochemical changes relate to prevention of 
atrophy by CsA and the augmentation of hyperplasia 
(21) is not clear. A simple explanation would be that the 
better response to a fructose load simply reflects the 
increased function under CsA of more healthful and 
more plentiful hepatocytes. However, a more sophisti-
cated hypothesis may be forthcoming now that infor-
mation exists concerning the action of drugs like CsA 
and FK 506 on cis-trans peptidyl-prolyl isomerase, an 
enzyme at the cytosolic binding sites for these agents. 
Peptidyl-prolyl isomerase inhibition or activation seems 
to have a wide-ranging effect on cell physiology, in-
cluding responsibility for the so-called hepatotrophic 
mechanisms and control of carbohydrate metabolism 
(33). 
Meanwhile, it must be remembered that cyclosporine 
is not a panacea for the liver. The drug can also be 
hepatotoxic even at therapeutic doses (1-10), impair 
hepatocyte transport processes (34, 35) or have an 
adverse effect on intracellular membranes (36, 37) after 
having gained entrance to the cells by passive diffusion 
(38). It is probable that CsA can be either hepatotrophic 
or injurious to the liver, depending on the dose. 
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